Depotwettbewerb USA 31 - 34 KW
Seite 3 von 5 Neuester Beitrag: 24.04.21 23:13 | ||||
Eröffnet am: | 27.07.03 19:39 | von: Eskimato | Anzahl Beiträge: | 122 |
Neuester Beitrag: | 24.04.21 23:13 | von: Danieladtkca | Leser gesamt: | 13.622 |
Forum: | Börse | Leser heute: | 12 | |
Bewertet mit: | ||||
Seite: < 1 | 2 | | 4 | 5 > |
CKSW 9900 Stück zu SK 2.27 $ = 22473 $
SWBD 3000 Stück zu SK 6.38 $ = 19140 $
MCTR 9900 Stück zu SK 2.95 $ = 29205 $
HMSL 13413 Stück zu SK 0.65$ = 8718.45 $
Grüße Reiny
XINGE in der Nachbörse über 8 Dollar, CTCH angezogen und ein Pinksheets-Aufpasser? Kenner? Glücksgriffler? ist doch ne Bereicherung fürs Forum und den Wettbewerb.
Seit AAC von Grueni zu 0,08 genommen wurde und dann bis 1 Dollar gelaufen ist, habe ich keine Einwände mehr gegen 0,0?
Ich sach ma so wie XYBR, oder CTCH gegen EZEN, beide waren auch bei 0,06, jetzt sind beide bei ca. 0,85.
Da kann ich nix mehr gegen Pennys haben.
Gruss E.
IDENTA LTD - Nasdaq Other OTC: IDTA
Consolidated Real-time Market Quote*
Last | Change (%) | After Hours Chg (%)** | Bid | Ask | Trade Time |
-- | -- | -- | -- | -- | -- |
Exchange Quote
Last | Change (%) | Bid (size) | Ask (size) | Trade Time |
0.0065 | ![]() | 0 (0) | 0 (0) | 15:52 |
Day Volume | Last Size | Open | High | Low |
16,248,900 | 50,000 | 0.004 | 0.007 | 0.004 |
Latest Ticks | # of Trades | Avg Trade Size | VWAP | 52 Wk High |
=+-+ | 114 | 142,534 | 0.0059 | 0.0095 |
52 Wk Low | Prev Close | Avg Day Vol | ||
0.0001 | 0.0038 | N/A |
8:08:43 PM EDT - Monday, August 4, 2003- Exchange quote is delayed
Identa Corp. Announces the Start of Field Tests of Its Drug Detection Kits With the National Authorities in Chile | ![]() |
THURSDAY, SEPTEMBER 19, 2002 10:23 AM - PR Newswire JERUSALEM, Sep 19, 2002 /PRNewswire-FirstCall via COMTEX/ -- Identa Corp. (OTC Pink Sheets: IDTA), a Florida corporation, announces the start of field tests of its Drug Detection Kits with the national authorities in Chile. A spokesperson for the company has announced that the company had reached an agreement with three national authorities in Chile whereby such authorities will start to test the company's kits in the field. The company's CEO, Mr. Yaacov Shoam, stated, "This is another milestone achievement for the Company, and I am confident that this testing will lead to sales of our drug detection kits in Chile and other national organizations and that out kits will replace the mistral-spray and nik-ampoules drug detector kits which are currently being used." It is estimated that the potential market size for the company's kits with the law enforcement agencies in Chile is approximately 75,000-90,000 kits per year. The company's kits provide many superior advantages to the kits currently on the market, which are being used by the national authorities in Chile. The company's kits have lot more accurate results and do not have false "positive" results, are a lot easer and simpler to use and are extremely more time efficient in getting a definite result (results in seconds). In addition, the company's kits show lab level results immediately, are more cost effective, and there is no downtime at laboratories, and can be used to detect extremity minute amounts. Furthermore, the kits are made of a durable plastic design, are easy and safe to use, and are environmentally safe. About Identa Ltd. Identa Ltd. develops, manufactures, and distributes on-site drug-of-abuse (DOA) testing products to government, law enforcement, and civilian markets. Identa's founders are experienced in forensic product design and development, and the company has spent the last six years developing and testing an innovative line of rapid DOA field tests. Forward-Looking Statements Certain statements in this news release may constitute "forward-looking" statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Such forward-looking statements involve risk, uncertainties and other factors, which may cause the actual results, performance or achievement expressed or implied by such forward-looking statements to differ materially from the forward-looking statements. Web Sites: www.drugsdetector.com or www.identa-forensics.com MAKE YOUR OPINION COUNT - Click Here http://tbutton.prnewswire.com/prn/11690X54623933 |
Immerhin gabs ne Pressemittteilung, dass CVS, eine Company aus dem S & P 500, die ersten 420 Kits jetzt bestellt hat.
Und die Polizei aus Rumänien und Russland kommt bald zu Besuch bei Identa.
Gruss E.
immer selber setzen wolltest, bei NENG warst Du damsls in der fünften Kalenderwoche zu 1,50 ausgestoppt worden, eine der vielen Geschichtchen dieses Wettbewerbs.
Gruss E.
Ein weiter Pinksheets den man beobachten sollte ist DVPC! man beachte die letzte News mit Schlumbeger!
Es ist nicht alles Gold was glänzt aber es ist auch nicht alles Shit was Pink ist!
XINGE hat heute das Filing abgegeben, darum der nachbörsliche Anstieg. Erwarte morgen noch mehr!
Mein Depot bleibt unverändert!
Grüße an die Mitspieler!
QADSAN
OT: Tournigan Gold wird auch noch kommen! :-) aber heftig
Gruss E.
Medifast Reports Record July Revenues; Company Continues to Expand in Asia
OWINGS MILLS, Md., Aug 5, 2003 /PRNewswire-FirstCall via COMTEX/ -- Medifast,
Inc. (Amex: MED) announced today record revenues for the month of July. The
company generated revenues exceeding $2.2 million, a 133% increase versus the
same period last year. This occurred despite the company reducing its
advertising spending during the month, as it typically does due to seasonal
factors.
"We are delighted that we were able to show sequential revenue growth versus May
and to maintain the revenues that we had earlier in the year, as the summer
months are normally slower for our business," said Brad MacDonald, CEO of
Medifast. "Despite a planned reduction in advertising, we were able to report
strong results."
Medifast is planning a national TV, print and radio campaign that will
significantly boost revenues in the first quarter 2004 and help it expand its
distributor and physician network. Internationally, the Company is launching its
products into India, Hong Kong and Singapore in addition to its Malaysian
territory.
"Our strategic partnership with Elken will make Dr. Diet by Medifast one of the
strongest weight and disease management brands in Asia," said Mr. MacDonald.
The Company will ship over $2 million in revenues to Asia in 2003 and expects
significant growth in 2004.
This release contains forward-looking statements, which may involve known, and
unknown risks, uncertainties and other factors that may cause Medifast's actual
results and performance in future periods to be materially different from any
future results or performance suggested by these statements. Medifast cautions
investors not to place undue reliance on forward-looking statements, which speak
only to management's expectation on this date.
SOURCE Medifast, Inc.
Verkauf:
VSCI 9900 Stück zu 1.90 $ = 18810 $
Grüße Reiny
Da hab ich reichlich zu NVTL und SWIR mit Einstiegskursen reingesetzt, Wireless läuft.
Gruss E.
SBE Announces Four Design Wins; Diverse communications applications using Linux
SAN RAMON, Calif., Aug 4, 2003 (BUSINESS WIRE) -- SBE Inc., (Nasdaq: SBEI), a
leading supplier of high performance OEM networking solutions, today announced
four new design wins where a variety of its wide area networking (WAN) adapters
and communications controllers have been selected for integration into a broad
array of applications. Collectively, the incremental annual revenue to SBE from
these opportunities is expected to exceed $1.8 million in calendar year 2005.
Fixed Wireless. SBE's single port clear channel T1/E1 PCI adapter
(wanADAPT-1T1LP) has been integrated into wireless Internet solutions as the T1
uplink for service providers and carriers. This domestic rollout is one of the
largest deployments on record and proves that WiFi hotspots are not limited to
fast food chains and airports. SBE is currently shipping production volumes to
this customer and expects future annual revenue to reach $400,000.
Banking/Financial institutions gateway. SBE was recently selected to provide
multiple products to a leading supplier of innovative gateway solutions to the
financial industry. Based on a standard CompactPCI architecture, SBE's HighWire
400c/M processor hosts mass storage for video applications and controls the
video-over-IP while SBE quad T1/E1 PMC adapters connect remote offices together
and reduce the number of IP addresses needed for those remote sites. Shipments
are forecasted to reach 2000 systems annually starting in early 2004.
Enhanced 911 (E-911) wireless location technology. SBE's T3 module
(wanPTMC-256T3) has been chosen for deployment in Phase II of the Federal
Communications Commission's (FCC) E-911 mandate. The mandate requires that
carriers must determine a mobile 911 caller's location within 100 meters at
least 67% of the time, and within 300 meters at least 95% of the time. SBE's
customer is a leader in E-911 wireless location technology and is working in
conjunction with top wireless carriers for nationwide use for both CDMA and GSM
networks. The incremental recurring revenue from this business is expected to
hit $500,000 by 2005.
Low-cost, high-performance Linux routers. Recognized provider of commodity
routing solutions for remote offices and corporate backbones has teamed with SBE
to take advantage of SBE's wide spectrum of WAN interfaces, including T1/E1 and
T3/E3. SBE displaced one of its competitors by providing comprehensive support
and service along with superior product delivery lead times at reasonable
prices.
"SBE prides itself on readiness to serve the constantly changing needs of our
customers," comments Dan Grey, senior vice president of sales and marketing at
SBE. "Three of the four most recent design wins being Linux-based applications
is a testament to our commitment to that space. We plan to continue future
development on Linux-based products and other emerging technologies that enable
SBE to be well-poised for integration into next generation networking
applications."
To learn more about the products integrated into these applications and other
SBE products, visit SBE at Booth #1543 at the LinuxWorld Conference and Expo at
the Moscone Center in San Francisco from August 5-7, 2003.
About SBE
SBE architects and provides network communications solutions for an extensive
range of applied computing applications. SBE offers a robust portfolio of
standards-based WAN/LAN adapters and communications controllers designed to
enable optimal performance and rapid deployment across a full spectrum of next
generation networking systems. Based in San Ramon, California, SBE is a publicly
traded company (Nasdaq: SBEI) with products sold worldwide through direct sales,
OEMs and system integration partners. For additional information, please visit
www.sbei.com.
This news release contains certain forward-looking statements that involve risks
and uncertainties, including statements about new product features, market
opportunity for new products, and the demand for services that may be offered by
SBE's customers. Such statements are only predictions and the company's actual
results may differ materially from those anticipated in these forward-looking
statements. Factors that may cause such differences include, but are not limited
to risks related to rapidly changing product requirements, the introduction of
new products, market acceptance of the Company' products, and reliance on
strategic partners. These factors and others are more fully discussed in the
documents SBE files with the Securities and Exchange Commission, including SBE's
Annual Report on Form 10-K.
SBE and the SBE logo are registered trademarks of SBE, Inc. All other brand or
product names are trademarks or registered trademarks of their respective
holders.
SOURCE: SBE, Inc.
Hmmmmm ......
Ich kündige hiermit meinen 3. Wert unter SL an.
CXIN hat es nach HOMS und NMGC nun auch erwischt.
Darfste also zum SL ausbuchen.
3 Werte waren ja schon länger verkauft, also hab ich akt. noch 4 Werte im Depot.
SBEI, DWCH, BSQR und DLGS notierten zwar auch schon bedeutend fester, aber so is datt eben.
Heute haue ich nix mehr raus.
Hätte der Hund nich an den Baum gepink ......., hätte er den Hasen gehabt!
Gr.Gr.;-)
Letzte Runde hatte ich einiges zu EDET geschrieben und Quartalszahlen reingestellt, die hatten auch wieder so ein 8 K Filing, was steckt dahinter?
Gruss E.
This is the "current report" that is used to report the occurrence of any material events or corporate changes which are of importance to investors or security holders and previously have not been reported by the registrant. It provides more current information on certain specified events than would Forms 10-Q or 10-K.
Interpretive Responsibility:
Division of Corporation Finance - Office of Chief Counsel
SEC-Filings
![<img <img](http://www.bergstrasse.de/unterhaltung/grafik/broemme_archiv.jpg)
BSQR KK 1,19 akt. 1,26
DWCH KK 6,10 akt. 6,12
DLGS KK 2,01 akt. 2,54
SBEI KK 2,44 akt. 2,93
Da muss noch watt kommen, da muss noch watt kommen, da muss ..........!
;-)
Schönes erholsames Wochenende wünscht
![](http://www.gruenspan.de/logotop.gif)
Gruss E.
Am Donnerstag sollen es ja mal wieder weniger als 30 Grad werden, da kann ichs hier besser aushalten, krieg die Wärme gar nicht aus den Zimmern.
Grueni, hätte der Hund nicht SBEI ans Bein gepinkelt, oder wie war das?
Quadsans NOOF haben ja richtig gute Zahlen vorgelegt, geiler Chart.
Ansonsten ist meine Rübe nen bisschen ausgetrocknet, ich verzieh mich nach draussen in den Schatten.
Tschüss E.
Schönen Urlaub noch;ich gehe morgen wieder in`s Büro.
Deine erfolgreichste Aktie IDTA hat leider nur einen minimalen Depotanteil, die Gewichtung des Depots wirst Du überdenken müssen.
Gruss E.
SBEI KK 2,44 akt.SK 3,15 (5291) = 16666,-
DWCH KK 6,10 akt.SK 6,00 (2117) = 12702,-
DLGS KK 2,01 akt.SK 2,73 (6422) = 17532,-
---- -- ---- ------ ---- ------ = 46900
---- -- ---- ------ ---- ------ + 47491 (aus Posting 25)
---- -- ---- ------ ---- ------ = 94391
---- -- ---- ------ ---- ------ +
HOMS SL 3,26 ------ ---- (3489) = 11374
NMGC SL 2,36 ------ ---- (4835) = 11410
CXIN SL 0,05 ------ ---- 234709 = 11735
---- -- ---- ------ ---- ------ = 128910,- als Zwischensumme Cash !!
BSQR KK 1,19 ------ ---- (10848) verbleibt "noch" als einziger Wert im Depot!
Sommerflaute, Sommerflaute und nochmal Sommerflaute verordnen nun auch mir meine Aktivitäten insgesamt stärker einzuschränken.
Weiterhin viel Spiel- Spass und Boersen- Erfolg wünscht
Gruenspan
CardioTech Reaches Profitability, Reports 682% Increase in Revenues for the First Quarter of Fiscal 2004
WEDNESDAY, AUGUST 13, 2003 8:32 AM
- PR Newswire
WOBURN, Mass., Aug 13, 2003 /PRNewswire-FirstCall via COMTEX/ -- CardioTech International, Inc. (CTE) : reported estimated net income for the quarter ended June 30, 2003 of $83,000, as compared to a net loss of ($171,000) for the comparable prior year period For the three months ended June 30, 2003, the Company achieved a diluted and basic net income of approximately $0.01 per share, as compared to a diluted and basic net loss of ($0.02) per share for the same quarter last year.
CardioTech's first quarter profit was earned on revenues of $5,476,000 for the three months ended June 30, 2003 as compared to $802,000 for the comparable prior year period, an increase of $4,674,000. The increase in revenues is attributable to the accretive acquisition of Gish Biomedical, a wholly owned subsidiary, which contributed $4,359,000 in the three months ended June 30, 2003.
Additionally, revenues continued to grow at the CDT subsidiary. CDT product sales were $861,000 for the three months ended June 30, 2003, as compared to $480,000 for the comparable prior year period, an increase of $381,000 or 79%.
Overall revenues for the quarter increased 682% over the same period last year.
Dr. Michael Szycher, Chairman and CEO of CardioTech International, commenting on the record first quarter results, stated, "Our ongoing strategy of accretive, synergistic acquisitions has resulted in the Company's first operational profit. I am very proud of our management team at Gish and CDT. They have executed superbly in their respective divisions, keeping costs down while staying focused on the bottom line. Fundamentally, we are in excellent condition. With no debt, a strong cash balance, and now profitability, we are poised for continued top and bottom line growth."
He also added, "We are looking forward to the near-term launch of our wound dressing technologies, which address a $300 million annual market. We are also extremely pleased with recent clinical developments regarding our promising CardioPass(TM) coronary artery bypass graft."